|
|
Volumn 3, Issue 3, 2002, Pages 223-228
|
|
Novel molecular targets for systemic lupus erythematosus
a
a
a
a
a
Xeptagen SpA
(Italy)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIIDIOTYPIC ANTIBODY;
ANTIINFLAMMATORY AGENT;
ANTIMALARIAL AGENT;
AZATHIOPRINE;
CD16 ANTIGEN;
CHYMOTRYPSIN;
COMPLEMENT;
CORTICOSTEROID;
CYCLOPHOSPHAMIDE;
CYCLOSPORIN;
FC RECEPTOR;
GLUCOCORTICOID;
IMMUNOGLOBULIN G;
IMMUNOSUPPRESSIVE AGENT;
METHOTREXATE;
MONOCLONAL ANTIBODY;
PEPSIN A;
TETRAMER;
TG 19320;
TRIPEPTIDE DERIVATIVE;
TRYPSIN;
UNCLASSIFIED DRUG;
OLIGOPEPTIDE;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ANTIGEN ANTIBODY COMPLEX;
AUTOIMMUNE DISEASE;
CATARACT;
COMBINATORIAL CHEMISTRY;
CONTROLLED STUDY;
DEPRESSION;
DISEASE PREDISPOSITION;
DRUG BIOAVAILABILITY;
DRUG BLOOD LEVEL;
DRUG EFFICACY;
DRUG FORMULATION;
DRUG HALF LIFE;
DRUG MECHANISM;
DRUG STABILITY;
DRUG SYNTHESIS;
DRUG TARGETING;
DRUG URINE LEVEL;
EFFECTOR CELL;
FEMALE;
GLOMERULONEPHRITIS;
HUMAN;
IN VIVO STUDY;
INFECTION;
INFLAMMATION;
INSOMNIA;
KIDNEY INJURY;
MICROBIAL IMMUNITY;
MOLECULAR INTERACTION;
MOUSE;
MOUSE STRAIN;
MULTIPLE MYELOMA;
NAUSEA AND VOMITING;
NONHUMAN;
OSTEOPOROSIS;
PATHOGENESIS;
REVIEW;
RHEUMATOID ARTHRITIS;
SYSTEMIC LUPUS ERYTHEMATOSUS;
TISSUE INJURY;
VALIDATION PROCESS;
WEIGHT GAIN;
ANIMAL;
METABOLISM;
PATHOPHYSIOLOGY;
ANIMAL;
DRUG STABILITY;
HUMAN;
LUPUS ERYTHEMATOSUS, SYSTEMIC;
OLIGOPEPTIDES;
RECEPTORS, IGG;
ANIMALS;
HUMANS;
|
|
EID: 0036001051
PISSN: 13894501
EISSN: None
Source Type: Journal
DOI: 10.2174/1389450023347777 Document Type: Review |
|
Times cited : (6)
|
|
References (26)
|
